Pharma, Biotech, and Medical Devices

In the context of the changing drug and device landscape, innovators must

  • rethink their product development priorities, market access strategy, and commercial models
  • allocate R&D investments to products that meet radically different and uncertain payer requirements
  • measure and communicate their products' value propositions to a multitude of stakeholders.

At the same time, the emergence of value-based payment models provides an unprecedented opportunity for companies: They are no longer constrained by payment silos in creating and monetizing truly innovative products.

RHAS Capabilities

Quantitative Research

  • Comparative effectiveness research
  • Outcomes research
  • Economic modeling
  • Simulation modeling
  • Real-world data analysis

Qualitative Research

  • Expert consultation
  • Semistructured interviews
  • Focus groups
  • Policy analysis

Measurement and Reporting Tools

  • Key performance indicators
  • Patient-reported outcomes

Business Solutions

  • Value dossiers
  • Value-based payment models
  • Gain-sharing arrangements
  • New commercial models
  • Pricing strategy

Featured Publications